Anticholinergics and central nervous system effects: are we confused?
David R Staskin1, Edward Zoltan
1Department of Urology, Weill Cornell Medical College New York, NY.
Reviews in Urology
|January 31, 2008
Summary
Anticholinergic agents can affect the central nervous system (CNS), particularly in older adults with overactive bladder. Further research is needed to understand these cognitive risks at prescribed doses.
Area of Science:
- Pharmacology
- Geriatrics
- Neuroscience
Background:
- Anticholinergic agents are widely used for overactive bladder.
- Central nervous system (CNS) effects of these agents are known but require further investigation.
- Older adults with overactive bladder are particularly susceptible to cognitive impairment and CNS side effects.
Purpose of the Study:
- To investigate the central nervous system (CNS) effects of anticholinergic agents in older patients with overactive bladder.
- To emphasize the need for careful investigation into cognitive impairment risks.
- To highlight the importance of studying these effects at clinically relevant doses and durations.
Main Methods:
- Utilizing multiple, validated cognitive tests.
- Assessing acute and chronic administration of anticholinergic agents.
- Considering commonly prescribed dosing regimens with equivalent bladder potency.
Main Results:
- The study abstract does not contain specific results.
- Further research is indicated to elucidate the precise CNS effects.
- The complexity of anticholinergic effects necessitates detailed study.
Conclusions:
- Anticholinergic use in older adults with overactive bladder warrants careful monitoring for CNS side effects.
- Future studies should employ rigorous methodologies to assess cognitive function.
- Understanding drug metabolism and delivery systems is crucial for managing potential risks.
More Related Videos
Related Concept Videos
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.